PrEP in 2026 — your four options, costs, and how to start.

For most of the history of this epidemic, HIV prevention meant condoms, negotiation, and luck. That is no longer true. As of 2026 there are four FDA-approved medications that a person who does not have HIV can take to keep from acquiring it — two daily pills, one injection every two months, and one injection twice a year.4 Pre-exposure prophylaxis, or PrEP, is now one of the most effective preventive interventions in all of medicine, and the U.S. Preventive Services Task Force gives it a Grade A recommendation, the strongest grade it issues.13

This page is written for two overlapping audiences. If you are considering PrEP for yourself, you will find the four options side by side, what starting actually involves, what it costs, and what to do if the cost is the obstacle. If you are living with HIV, PrEP is part of your story too — it is what a partner may choose alongside your undetectable viral load, and it is one of the most concrete ways the conversation about mixed-status relationships has changed. Nobody here is a risk to anybody. This is about tools.

Why PrEP now — four options, and what U=U has to do with it

Two things changed the arithmetic of HIV prevention, and they arrived from opposite directions.

The first is treatment as prevention. A person living with HIV who takes antiretroviral therapy and maintains an undetectable viral load does not transmit HIV sexually. That is the finding behind Undetectable = Untransmittable, and it is reflected in federal clinical guidance: for partners with different HIV status, when the partner with HIV is on antiretroviral therapy and has achieved sustained viral suppression, sex without a condom allows conception without sexual HIV transmission to the partner who does not have HIV.18 Viral suppression is prevention, and it belongs to the person living with HIV.

The second is PrEP, which belongs to the person who does not have HIV. It works whether or not a partner is diagnosed, whether or not a partner is in care, and whether or not you know a partner's status at all. It covers the situations U=U cannot — a new partner, an unknown status, a night that was not planned, a relationship where disclosure is not safe.

Put together, these two facts mean that a mixed-status couple in 2026 has redundant, independent protection available: the partner living with HIV stays suppressed, and the partner who does not have HIV can take PrEP if they want it. Many couples choose both. Some choose one. Both are legitimate, and the choice belongs to the people in the relationship, not to a clinician's judgment about them.

What is genuinely new is choice. In 2012 PrEP meant one pill, every day, forever. In 2026 it means a menu: two pills with different profiles, an injection every eight weeks, and an injection every six months.4 That matters because daily adherence is not a character trait — it is a function of housing, work schedules, privacy, side effects, insurance renewals, and whether a pill bottle in a shared bathroom is safe. The long-acting options were developed precisely because a very effective drug that people cannot keep taking is not, in the real world, very effective. As the New England Journal of Medicine editorial accompanying the first lenacapavir trial put it, high efficacy in a trial "is great news for science but not (yet) great for women" until access and delivery catch up.12

The four options, side by side

Here is the whole menu in one place. Every value in this table comes from the FDA labels, CDC clinical guidance, or published wholesale pricing — sourced individually below.

Truvada and generic F/TDF — the workhorse

Emtricitabine/tenofovir disoproxil fumarate is the option with the longest track record and the broadest indication. FDA labeling added a PrEP indication in 2012, and the current label covers adults and adolescents weighing at least 35 kg to reduce the risk of sexually acquired HIV-1.5 CDC lists it as the regimen for all routes of sexual exposure and for injection-related exposure — the only option with that breadth.3 It is also the only option available as a generic, which makes it dramatically cheaper than everything else on the list.16

The trade-offs are kidney function and bone. CDC sets an estimated creatinine clearance threshold above 60 mL/min for F/TDF, and the label carries a warning about decreases in bone mineral density, advising assessment in people with a history of pathologic fracture or other risk factors for bone loss.35 Because tenofovir is also active against hepatitis B, hepatitis B serology is part of the baseline workup for either oral option.3

Descovy — narrower indication, gentler on kidneys and bone

Emtricitabine/tenofovir alafenamide was approved for PrEP on October 3, 2019.6 The label indication is deliberately narrower: it covers sexual acquisition excluding people at risk from receptive vaginal sex, because effectiveness in that population was not evaluated in the registration trial.6 That is not a technicality. Federal perinatal guidance goes further and states the panel does not recommend TAF/FTC as PrEP for people with vaginal exposure, including during pregnancy and postpartum.18 Anyone who has receptive vaginal sex — including transgender men and nonbinary people — should be offered F/TDF, cabotegravir, or lenacapavir instead.

What you get in exchange is a lower kidney threshold — CDC lists F/TAF as usable down to an estimated creatinine clearance of 30 mL/min — and less effect on bone. The trade is metabolic: CDC recommends checking lipids and weight annually on F/TAF.3

Apretude — cabotegravir every two months

Long-acting injectable cabotegravir was first approved in the United States in 2021, and the original label already covered "at-risk adults and adolescents weighing at least 35 kg."7 Dosing is a 600 mg (3 mL) gluteal intramuscular injection at month 1 and month 2, then every two months, with a seven-day window on either side of the target date. An optional 28-day oral lead-in with cabotegravir tablets is available for people who want to test tolerability before committing to an injection.7

Cabotegravir requires no kidney assessment, and CDC recommends it instead of oral PrEP for someone whose estimated creatinine clearance is below 30 mL/min.3 Injection-site reactions are common — 81.4% in the trial among men who have sex with men and transgender women, versus 31.3% in the oral comparison group — and were mostly pain at the injection site.10 Follow-up is more frequent than with oral PrEP in one respect: HIV testing happens at every injection visit, so every two months.3

Yeztugo — lenacapavir, twice a year

Lenacapavir is an HIV capsid inhibitor, a mechanism unlike anything else in PrEP. Starting it takes two days: on day 1, two 1.5 mL subcutaneous injections totaling 927 mg, given at least four inches apart in the abdomen or anterior thigh, plus two 300 mg tablets; on day 2, two more 300 mg tablets. After that, it is one set of injections every 26 weeks, with a two-week window.12

Protection arrives fast if the oral loading doses are taken — CDC cites limited data suggesting protective levels about two hours after the day-2 dose. Skip both oral days and it takes an estimated 21 to 28 days.2 Injection-site reactions were the dominant side effect, reported by 68.8% of participants in one trial and 83.2% in the other, mostly mild to moderate pain, firmness, and subcutaneous nodules; nodules can be several centimeters across and last months. Symptoms decreased with later injections, and discontinuation because of them was uncommon — 0.2% and 1.2%.2 Ice packs and analgesics before and after the injection may help.2

One practical wrinkle that affects access more than it affects safety: because lenacapavir has to be injected by a clinician, it moves through specialty distributors rather than your neighborhood pharmacy, and insurers frequently treat it as a medical benefit rather than a pharmacy benefit.15 That has real consequences for cost, covered below.

What the trials actually found

PrEP effectiveness numbers get quoted loosely, so here are the primary results, with the comparison each number was measured against.

But, the results of the PURPOSE 1 trial have now created a moral imperative to make lenacapavir broadly accessible and affordable as PrEP to persons who were enrolled, as well as all those who are similarly eligible and could benefit. — Rochelle P. Walensky, MD, MPH, and Lindsey R. Baden, MD, editorial accompanying the PURPOSE 1 results, New England Journal of Medicine, 2024.12

Who should consider PrEP — and why nobody should have to justify it

CDC's clinical guidance is unusually direct on this point, and it is worth quoting the substance of it. Clinicians should inform all sexually active adult and adolescent patients about PrEP. And they should prescribe PrEP to anyone who asks for it, including people who do not report any of the recognized reasons for needing it.3 There is no scoring tool you have to pass. There is no disclosure quota. Asking is sufficient.

The Task Force describes the circumstances where PrEP is clearly indicated, which are useful mainly as a prompt for conversation. Sexually active adults and adolescents weighing at least 35 kg who have had anal or vaginal sex in the past six months and any of the following: a partner who has HIV, especially if the partner's viral load is unknown or detectable; a bacterial sexually transmitted infection in the past six months; or inconsistent or no condom use with partners whose status they do not know.13 CDC's guidance adds people who have injected drugs in the past six months and shared equipment or had an injecting partner with HIV.3

Two clarifications that come up constantly in mixed-status relationships:

• A suppressed partner is not a reason to withhold PrEP. CDC says explicitly that PrEP should not be withheld from someone whose partner with HIV is virally suppressed.3 If the partner without HIV wants PrEP, that is a complete reason to prescribe it.
• You do not need a specialist. Any licensed prescriber can prescribe PrEP.3 In Arkansas, California, Colorado, Illinois, Maine, Nevada, Oregon, Utah, and Virginia, pharmacists can prescribe it directly.4

There is also an equity number worth naming. Analysis of the ACA preventive-services litigation notes that only about 36% of people who could benefit from PrEP in the United States are prescribed it, and that more than 80% of current PrEP users have commercial insurance.14 The gap between who needs PrEP and who gets it is not a gap in the science.

Starting PrEP — the labs, the visit, and the follow-up rhythm

The single non-negotiable requirement is a confirmed negative HIV test immediately before starting. All four medications carry a boxed warning about the risk of drug resistance if PrEP is used by someone with undiagnosed HIV.15 This is why the testing schedule is strict — not because anyone doubts you.

Baseline, for oral PrEP

• HIV antigen/antibody test plus HIV-1 RNA — the RNA test catches very recent infection that antibody testing can miss.3
• Chlamydia, gonorrhea, and syphilis screening.3
• Kidney function by estimated creatinine clearance — above 60 mL/min for F/TDF, at least 30 mL/min for F/TAF.3
• Hepatitis B serology before either oral option, because both are active against hepatitis B.3
• Lipids if starting F/TAF.3

Baseline, for injectable PrEP

For lenacapavir, CDC asks for a laboratory blood-based antigen/antibody test on the day of the first injection, or within the preceding seven days, plus a confirmatory HIV RNA test if available — and explicitly says the RNA result should not delay the injection. If RNA testing is not available, repeat the antigen/antibody test in four weeks. Oral rapid antibody tests should not be used, because their sensitivity for recent infection is too low.2 No kidney assessment is required for either injectable.3

How long until it works

For daily oral PrEP, CDC estimates about seven days of daily dosing to reach protective levels for receptive anal sex, and up to about 21 days for receptive vaginal sex and injection-related exposure.3 For lenacapavir with the two oral loading days, protective levels are reached roughly two hours after the day-2 dose.2

The follow-up rhythm

• Oral PrEP: HIV antigen/antibody plus RNA testing at least every three months, with prescriptions limited to 90 days. Kidney function every six months if you are 50 or older or started with an eCrCl below 90, otherwise every 12 months. Lipids and weight annually on F/TAF.3
• Cabotegravir: HIV testing at month 1, then at every injection — every two months.3
• Lenacapavir: a blood-based antigen/antibody test before every injection, so every six months, with an initial one-month check worth considering. CDC also notes that more frequent contact — texts, phone calls — is often useful early on.2

Every visit is also an opportunity for sexually transmitted infection screening at the sites that apply to you — throat, rectum, vagina, urine, blood — and CDC suggests STI screening may need to happen more often than PrEP visits do, plus consideration of doxycycline post-exposure prophylaxis.2

Adherence, realistically

Adherence is a logistics problem far more often than a motivation problem, and the trial data make that unusually clear. In PURPOSE 1, adherence to both daily oral arms was low — in a supported clinical trial, with free medication and staff who called.8 That is not a story about young women in South Africa. It is a story about daily pills.

Some honest specifics about forgiveness:

• Daily oral PrEP is the least forgiving option. Protection wanes over roughly seven to ten days after you stop taking it.3 Drug levels also build more slowly in vaginal and rectal tissue than in blood, which is why the estimated time to protection is longer for receptive vaginal sex — about 21 days — than for receptive anal sex.3 The practical implication is that fewer doses per week leaves less margin for someone whose exposure is through receptive vaginal sex than for someone whose exposure is through anal sex.
• Cabotegravir gives you a week of slack on either side of an eight-week target date.7
• Lenacapavir gives you two weeks on either side of a 26-week target, and there is a documented bridge if you are going to miss: 300 mg orally every seven days, for up to six months, starting six months after your last injection, then resume injections within seven days of the last tablet.2

On-demand "2-1-1" dosing

Event-driven PrEP — two pills 2 to 24 hours before sex, one pill 24 hours after the first dose, one more 24 hours after that — was tested in the French ANRS IPERGAY trial. Among 400 men who have sex with men, there were 2 infections on TDF-FTC (0.91 per 100 person-years) versus 14 on placebo (6.60 per 100 person-years), an 86% relative reduction (95% CI 40–98; p=0.002). The two breakthrough infections occurred in men who had stopped taking the pills.19

Where it fits in the United States is narrower than people assume. CDC describes 2-1-1 as an off-label option that clinicians may prescribe for adult gay and bisexual men, using F/TDF only — and states plainly that it is not FDA-approved and not recommended by CDC. It is not appropriate for people with active hepatitis B, for adolescents, or for people with active substance use disorder, and there are no data supporting it with F/TAF.3 If event-driven dosing appeals to you because daily pills do not fit your life, the long-acting injectables are the better-evidenced answer.

Cost and insurance — what you should actually pay

The rule most people have never been told: because the Task Force gives PrEP a Grade A recommendation, the Affordable Care Act requires most health plans to cover it without cost-sharing.1315 HIV.gov states that under almost all health insurance plans PrEP is free, with no copayment or coinsurance, even before you meet your deductible — and that this covers the medication, the clinic visits, and the required lab work. Medicare Part B covers PrEP with no cost-sharing.4

That requirement survived a serious challenge. In Kennedy v. Braidwood Management, decided June 27, 2025 by a 6–3 vote, the Supreme Court upheld the constitutionality of the Task Force's structure, preserving the no-cost-sharing requirement for A- and B-graded preventive services for roughly 100 million privately insured people.14 Important caveats remain: the ruling confirmed that the Secretary of Health and Human Services may remove Task Force members at will, related claims about other advisory bodies were sent back to lower courts, and the plaintiffs' religious-objection claims specific to PrEP were not decided.14 The protection is real and it is not permanent.

The lenacapavir coverage gap

Here is where 2026 gets complicated. NASTAD reports that payers are splitting on whether the 2023 Task Force recommendation reaches Yeztugo, because the evidence review was completed before lenacapavir was approved. A broad reading covers "PrEP with effective antiretroviral therapy" and therefore all approved options; a strict reading limits it to the three medications reviewed. The practical result is that many plans are not applying the zero-cost-sharing rule to Yeztugo, and some require prior authorization or apply copayments, coinsurance, and deductibles. Several states have passed laws requiring state-regulated plans to cover all FDA-approved PrEP options without cost-sharing, but those laws do not reach every plan, including some self-funded employer plans.15

Because lenacapavir is clinician-administered, insurers often treat it as a medical benefit, where a flat 20% coinsurance after the deductible is common. State Medicaid programs must cover it, with cost-sharing that is typically nominal. For Medicare, it falls under Part B as a provider-administered drug, where a beneficiary can owe up to 20% after the deductible unless supplemental coverage, Medicaid dual eligibility, or the Qualified Medicare Beneficiary program helps.15

If you are uninsured or underinsured

One important correction to a lot of older material still circulating: Ready, Set, PrEP has ended. The federal program stopped accepting new enrollments on July 30, 2024 and closed entirely on July 18, 2025.17 Anyone pointing you to getyourprep.com is working from outdated information. What exists instead:

• Manufacturer patient assistance programs for people without coverage, and copayment assistance programs for people with insurance. Per HIV.gov, as of January 2026: Gilead's programs cover Truvada, Descovy, and Yeztugo at 800-226-2056, with an income ceiling of 500% of the federal poverty level for patient assistance and annual copay caps of $7,200 for the pills and $8,000 for Yeztugo plus up to $100 toward administration costs. ViiV covers Apretude at 844-588-3288, also at 500% FPL, with a $7,500 annual copay cap plus up to $350 for administration. Enrollment lasts 12 months and most programs require annual renewal.16
• Generic emtricitabine/tenofovir disoproxil fumarate. Discount-card pricing for a 30-day supply of the 200 mg/300 mg generic has been listed under $30, against a retail price of roughly $2,100 — the single largest cost lever available.16
• Federally qualified health centers and 340B pricing. Yeztugo is subject to 340B discounts, so federally funded HIV prevention programs and FQHCs can purchase it at a substantially reduced ceiling price and use the savings to support care.15 This is why a community health center is often cheaper than a private practice for the same medication.
• State PrEP assistance programs and health department clinics, which vary widely — see the Florida section below for one working example.

A gap worth naming out loud: assistance programs generally cover the drug, not the visit or the labs.16 If cost is the barrier, ask specifically about visit and lab coverage, not just medication.

PrEP navigators, community health centers, and telehealth

A PrEP navigator is a staff member — sometimes a community health worker, sometimes a nurse or case manager — whose job is the part of PrEP that is not medicine: insurance verification, enrollment paperwork, prior authorizations, appointment reminders, transportation, and the follow-up call after the first prescription. It is unglamorous and it works.

In a randomized pilot among 60 Black gay and bisexual men newly prescribed PrEP in the southern United States, a single navigation session plus twice-monthly check-ins made participants meaningfully more likely to pick up the first prescription (relative risk 1.47; 95% CI 1.10–1.97), more likely to still be in PrEP care at three months (RR 1.62; 95% CI 1.01–2.59), and three times as likely to have medication on hand for more than 80% of study days based on pharmacy fill records (RR 3.00; 95% CI 1.50–5.98).20 A single conversation and some phone calls tripled the odds of continuous coverage.

Where to find one

• Ryan White–funded clinics and federally qualified health centers are the most likely places to have navigation staff already on payroll, and the HRSA health center finder plus the HIV.gov services locator will identify them near you.16
• County and state health departments. In Florida, all 67 county health departments provide PrEP counseling, medication, and follow-up testing, with medication provided at no cost to the client from the state's supply.22
• Telehealth. Florida's health department launched a TelePrEP program in 2020 so that people can access PrEP services through the county health department system via a dedicated telehealth practitioner team, and its clinical guidance lists direct telehealth contacts for clinicians arranging a visit.2221
• The clinician consultation line. If your provider is unfamiliar with any of this — particularly the newer injectables — they can call the PrEPline at 1-855-448-7737 for free expert consultation.3

One more access route matters for injectables specifically. When a person's usual PrEP provider cannot administer injections, NASTAD describes alternate sites of care that handle purchasing, dispensing, and administration on their behalf.15 "My doctor doesn't do shots" is a solvable problem, not a dead end.

Adolescents — all four options, by weight not age

This section exists because the guidance in circulation is inconsistent, and young people get turned away on the basis of the outdated version.

The FDA labels are the controlling documents, and all four medications are indicated for adolescents by weight rather than age. Truvada: adults and adolescents weighing at least 35 kg.5 Descovy: the same weight threshold, with the receptive-vaginal-sex exclusion.6 Apretude: at-risk adults and adolescents weighing at least 35 kg, a scope present in the original 2021 label; 59 adolescents were enrolled in its trials and 54 received at least one injection.7 Yeztugo: adults and adolescents weighing at least 35 kg from the date of its June 2025 approval, with 128 adolescents enrolled across PURPOSE 1 and PURPOSE 2 and 59 receiving lenacapavir.1

CDC's September 2025 lenacapavir recommendation is written the same way — the population covered is adults and adolescents weighing at least 77 lb (35 kg) who would benefit from PrEP, with no separate adolescent restriction.2 The Task Force also frames its Grade A recommendation by weight, covering adults and adolescents at increased risk weighing at least 35 kg.13

Two practical notes for young people. First, bone: the F/TDF label advises considering bone mineral density assessment in anyone with a history of pathologic fracture or other risk factors for bone loss, which is worth discussing when the person starting PrEP is still growing.5 Second, consent: Florida's own PrEP guidance states that health department employees may not provide PrEP prescriptive services to people under 18 without parental consent — a state administrative rule, not a clinical one, and one reason a community health center or an adolescent-medicine clinic may be a better route for a minor in Florida.21

Pregnancy, breastfeeding, and trying to conceive

Pregnancy raises the stakes in both directions: acquiring HIV during pregnancy or breastfeeding carries a higher risk of passing it to the baby, and every medication decision now involves two people.

Federal perinatal guidance is specific. The preferred PrEP option for people who have receptive vaginal sex during pregnancy and breastfeeding is daily tenofovir disoproxil fumarate/emtricitabine, rated AII. The panel does not recommend TAF/FTC as PrEP for people with vaginal exposure, including during pregnancy and postpartum, because efficacy studies in this population have not been completed. Anyone who becomes pregnant while taking TDF/FTC as PrEP can continue it. For someone planning a pregnancy who needs PrEP, TDF/FTC is recommended whenever possible; for someone already using long-acting cabotegravir, the guidance is to discuss whether to continue or switch. Clinicians are strongly encouraged to report pregnancies during PrEP use to the Antiretroviral Pregnancy Registry.18

What is known about the newer options is limited but not empty. For lenacapavir, CDC reports that the available human data suggest no increase in drug-associated risk for adverse pregnancy, birth, or infant outcomes compared with daily tenofovir-based PrEP or background rates, and that lenacapavir PrEP may be used in pregnancy or continued if someone becomes pregnant while receiving injections, after shared decision-making that accounts for their risk of acquiring HIV without PrEP.2 The label's underlying data: among 208 pregnancies with known outcomes in PURPOSE 1, there were 132 deliveries and 2 major birth defects — both ventricular septal defects — within the background rate. In lactation, the median milk-to-plasma ratio was 0.63, and infant-to-mother plasma ratio 0.06.1

For cabotegravir, the label is candid that human pregnancy data are insufficient to assess drug-associated risk.7 There is separately a signal from perinatal guidance worth knowing if you switch from cabotegravir PrEP to treatment: because of concerns about integrase inhibitor resistance mutations, someone with a history of cabotegravir PrEP exposure who starts HIV treatment has a different preferred first regimen than someone without that history.18

And the part that gets lost: conception itself. Federal guidance states that when the partner with HIV is on antiretroviral therapy with sustained viral suppression, sex without a condom allows conception without sexual HIV transmission to the partner who does not have HIV, rated BII.18 Mixed-status couples can conceive the ordinary way. PrEP is available as an additional layer if the partner without HIV wants it — not as a correction to anyone.

Stopping, restarting, and the pharmacologic tail

Stopping PrEP is a normal thing to do. Circumstances change. What matters is doing it in a way that does not leave a gap or create a resistance risk.

Oral PrEP

Protection wanes over roughly seven to ten days after the last dose.3 The practical guidance is to continue for a period after your last exposure rather than stopping the same day, and to talk with your prescriber about the right interval for your situation. If you have hepatitis B, stopping tenofovir is a decision that needs planning, because it treats hepatitis B as well.3 Restarting oral PrEP is straightforward — a negative HIV test and the same time-to-protection window as the first time.

Cabotegravir

Residual drug concentrations may remain for 12 months or longer after the last injection, so the label directs that alternative PrEP be started within two months of the final injection.7 CDC is more specific for the transition: prescribe daily oral PrEP within eight weeks of the last cabotegravir injection, and continue quarterly visits with antigen/antibody and RNA testing for 12 months after the last injection.3 That year of testing exists because the long tail means that if someone acquires HIV while drug levels are declining, the virus is exposed to a single drug at a subtherapeutic level — the classic recipe for resistance, and something HPTN 083 documented in breakthrough infections.10

Lenacapavir

The tail is longer still. CDC describes drug levels declining over 18 months, beginning six months after the last injection, with no HIV protection after the six-month mark — so the window where you are unprotected but still have drug in your body is substantial.2 The label directs that alternative PrEP be started within 28 weeks of the last injection, and notes that lenacapavir can affect the levels of certain other medications processed by CYP3A for up to nine months.1

If an injection is going to be more than 14 days late, there is a planned bridge: 300 mg orally every seven days for less than six months, with the first tablet six months after the last injection and injections resuming within seven days of the last tablet. If oral bridging is not workable, use a different form of PrEP until injections restart. If more than 14 days have passed and no bridging tablets were taken, restarting means going back to the beginning — eligibility assessment, HIV antigen/antibody and RNA testing, and the full loading dose again.2

The through-line for all three long-acting scenarios: plan the exit before you need it. Ask at your first injection visit what the off-ramp looks like, so the answer already exists on the day your insurance changes or you move.

Florida — where access is better than the reputation, and where it isn't

Florida is one of the highest-burden states in the country and, at the same time, has one of the more expansive public PrEP infrastructures. Both things are true.

Since 2018, all 67 county health departments provide PrEP services — counseling, medication, and follow-up testing — with medication provided at no cost to the client from the state's supply. The state's own integrated plan reports that more than 11,319 county health department clients had received PrEP medication through the program.22 The state PrEP clinical guidance directs that all sexually active adult and adolescent patients receive information about STIs, PrEP, and post-exposure prophylaxis, and it also created a mechanism — program component "02H" — for county health departments to charge PrEP-related HIV, hepatitis, and STI lab costs to the state HIV/AIDS Section for people who cannot afford them, while funding lasts.21

For medication assistance more broadly, Florida covers HIV medication costs directly for individuals at or below 400% of the federal poverty level.22 The statewide HIV/AIDS information line is 1-800-352-2437, with Spanish at 1-800-545-SIDA and Creole at 1-800-AIDS-101.22

The gaps are worth naming with the same specificity. Florida's own quick-reference materials cite a CDC estimate of roughly 125,330 Floridians who could benefit from PrEP in 2020, against about 21,479 receiving it — a coverage rate under one in five.22 The state's PrEP guidance carries the same superseded language about injectable PrEP not having been studied under 18, and bars health department staff from prescribing PrEP to minors without parental consent.21 County programs also differ substantially in hours, walk-in availability, and which options they stock, so calling ahead about the specific medication you want — particularly either injectable — is worth the phone call.

The U=U connection — two independent layers

If you are living with HIV and reading a PrEP page, this is the section that is about you.

U=U and PrEP are two separate protections that happen to point at the same outcome. Viral suppression means a person living with HIV does not transmit HIV sexually — the finding embedded in federal guidance that a suppressed partner and a partner without HIV can have sex without a condom, and conceive, without sexual transmission.18 PrEP is protection the partner without HIV carries independently, effective regardless of anyone else's viral load, appointment schedule, or pharmacy hold.4

Couples choose different combinations for reasons that are usually emotional rather than epidemiological, and that is fine. Some couples use both because the partner without HIV wants something in their own hands during the months after a diagnosis, while the regimen is still being sorted out. Some use both because a viral load is a number from three months ago and lab schedules slip. Some use both because one partner has other partners. And many couples, once suppression is stable and trusted, use U=U alone — which is a scientifically sound choice, not a shortcut.

What matters is that neither choice is a verdict on anybody. A partner starting PrEP is not saying they distrust you. A partner declining PrEP is not saying they are careless. Two people using two independent tools is just good engineering. And the one framing to reject entirely: PrEP is not protection from a person. It is protection from a virus, held by whoever wants to hold it.

One clinical note that belongs here rather than buried in a label: if someone taking PrEP does acquire HIV, the priority is fast diagnosis and immediate treatment, and for infections acquired on lenacapavir CDC advises considering integrase inhibitor–based therapy.2 This is precisely what the frequent testing schedule is for. A PrEP failure is not a moral event; it is a clinical one with a defined next step.

Start here

If you have decided you want PrEP, or you are helping someone who has:

1. Get a blood-based HIV test. Antigen/antibody, not an oral swab, and ask whether an HIV-1 RNA test can be drawn at the same visit. Nothing else can start until this is done.2
2. Ask any licensed prescriber for PrEP by name. Primary care, an STI clinic, a county health department, a community health center, a telehealth program, or — in nine states — a pharmacist.34 Say which option you are interested in and why. If you get a lecture instead of a prescription, that is a reason to change clinics, not a reason to give up.
3. Verify coverage before you leave the building. Ask which option is covered at $0 under your plan, whether prior authorization is needed, and — for either injectable — whether the drug runs through your medical or pharmacy benefit.15 If you are uninsured or the cost is wrong, ask the clinic to enroll you in a manufacturer program the same day.16
4. Ask for a navigator by name. Ryan White clinics, federally qualified health centers, and county health departments are the most likely to have one, and the evidence says navigation substantially improves the odds you actually stay on PrEP.20
5. Put the follow-up in your calendar before you leave. Every three months for oral PrEP, every two months for cabotegravir, every six months for lenacapavir — and ask what happens if you are going to miss one, so the answer exists before you need it.32

Community publications including POZ, Positively Aware, and TheBody have covered what starting and staying on PrEP actually feels like from the inside for years — worth reading alongside the clinical guidance, which is excellent at protocol and quiet about the rest.